|
Gene: TOX2 |
Gene summary for TOX2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TOX2 | Gene ID | 84969 |
Gene name | TOX high mobility group box family member 2 | |
Gene Alias | C20orf100 | |
Cytomap | 20q13.12 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96NM4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84969 | TOX2 | P2T-E | Human | Esophagus | ESCC | 3.95e-03 | 1.60e-01 | 0.1177 |
84969 | TOX2 | P4T-E | Human | Esophagus | ESCC | 1.29e-02 | 1.12e-01 | 0.1323 |
84969 | TOX2 | P8T-E | Human | Esophagus | ESCC | 1.32e-02 | 1.47e-01 | 0.0889 |
84969 | TOX2 | P10T-E | Human | Esophagus | ESCC | 5.24e-07 | 2.02e-01 | 0.116 |
84969 | TOX2 | P11T-E | Human | Esophagus | ESCC | 1.88e-13 | 5.16e-01 | 0.1426 |
84969 | TOX2 | P15T-E | Human | Esophagus | ESCC | 2.95e-12 | 2.73e-01 | 0.1149 |
84969 | TOX2 | P17T-E | Human | Esophagus | ESCC | 1.11e-04 | 2.12e-01 | 0.1278 |
84969 | TOX2 | P19T-E | Human | Esophagus | ESCC | 4.41e-02 | 2.06e-01 | 0.1662 |
84969 | TOX2 | P20T-E | Human | Esophagus | ESCC | 6.29e-03 | 9.71e-02 | 0.1124 |
84969 | TOX2 | P24T-E | Human | Esophagus | ESCC | 4.00e-06 | 1.32e-01 | 0.1287 |
84969 | TOX2 | P26T-E | Human | Esophagus | ESCC | 9.87e-09 | 1.78e-01 | 0.1276 |
84969 | TOX2 | P31T-E | Human | Esophagus | ESCC | 1.35e-15 | 3.43e-01 | 0.1251 |
84969 | TOX2 | P32T-E | Human | Esophagus | ESCC | 4.38e-09 | 2.11e-01 | 0.1666 |
84969 | TOX2 | P40T-E | Human | Esophagus | ESCC | 1.59e-02 | 1.62e-01 | 0.109 |
84969 | TOX2 | P47T-E | Human | Esophagus | ESCC | 1.19e-03 | 6.75e-02 | 0.1067 |
84969 | TOX2 | P49T-E | Human | Esophagus | ESCC | 7.22e-13 | 8.67e-01 | 0.1768 |
84969 | TOX2 | P52T-E | Human | Esophagus | ESCC | 1.18e-15 | 3.61e-01 | 0.1555 |
84969 | TOX2 | P54T-E | Human | Esophagus | ESCC | 1.61e-04 | 1.80e-01 | 0.0975 |
84969 | TOX2 | P61T-E | Human | Esophagus | ESCC | 3.98e-07 | 2.17e-01 | 0.099 |
84969 | TOX2 | P62T-E | Human | Esophagus | ESCC | 3.35e-08 | 2.40e-01 | 0.1302 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00075656 | Prostate | BPH | female pregnancy | 54/3107 | 193/18723 | 4.64e-05 | 4.87e-04 | 54 |
GO:00447066 | Prostate | BPH | multi-multicellular organism process | 59/3107 | 220/18723 | 8.01e-05 | 7.66e-04 | 59 |
GO:00018935 | Prostate | BPH | maternal placenta development | 14/3107 | 35/18723 | 8.33e-04 | 5.41e-03 | 14 |
GO:00601355 | Prostate | BPH | maternal process involved in female pregnancy | 19/3107 | 62/18723 | 4.41e-03 | 2.16e-02 | 19 |
GO:006145816 | Prostate | Tumor | reproductive system development | 133/3246 | 427/18723 | 1.24e-12 | 1.15e-10 | 133 |
GO:004860815 | Prostate | Tumor | reproductive structure development | 131/3246 | 424/18723 | 3.48e-12 | 2.89e-10 | 131 |
GO:000189016 | Prostate | Tumor | placenta development | 52/3246 | 144/18723 | 4.96e-08 | 1.52e-06 | 52 |
GO:000756514 | Prostate | Tumor | female pregnancy | 55/3246 | 193/18723 | 7.79e-05 | 8.11e-04 | 55 |
GO:004470613 | Prostate | Tumor | multi-multicellular organism process | 60/3246 | 220/18723 | 1.47e-04 | 1.34e-03 | 60 |
GO:000189313 | Prostate | Tumor | maternal placenta development | 14/3246 | 35/18723 | 1.30e-03 | 8.19e-03 | 14 |
GO:006013514 | Prostate | Tumor | maternal process involved in female pregnancy | 20/3246 | 62/18723 | 3.07e-03 | 1.63e-02 | 20 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TOX2 | SNV | Missense_Mutation | c.260N>G | p.Asp87Gly | p.D87G | Q96NM4 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A8-A0A9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
TOX2 | SNV | Missense_Mutation | c.1373C>G | p.Ser458Cys | p.S458C | Q96NM4 | protein_coding | deleterious(0.02) | possibly_damaging(0.855) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
TOX2 | SNV | Missense_Mutation | c.722N>T | p.Lys241Met | p.K241M | Q96NM4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
TOX2 | SNV | Missense_Mutation | novel | c.615N>A | p.Ser205Arg | p.S205R | Q96NM4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-E2-A576-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
TOX2 | insertion | In_Frame_Ins | novel | c.680_681insTATACACATATACACACATGCACACACACT | p.Asp227_Pro228insIleHisIleTyrThrHisAlaHisThrLeu | p.D227_P228insIHIYTHAHTL | Q96NM4 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
TOX2 | insertion | Frame_Shift_Ins | novel | c.810_811insTATACACACATGCACACACACTCCAAACTTGGAAATAG | p.Ala271TyrfsTer50 | p.A271Yfs*50 | Q96NM4 | protein_coding | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
TOX2 | insertion | Nonsense_Mutation | novel | c.695_696insTCTATTGGGCACTAACCAGTTTCACGTGTAATTTAGTAAT | p.Lys233LeufsTer10 | p.K233Lfs*10 | Q96NM4 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
TOX2 | SNV | Missense_Mutation | rs755716363 | c.362N>T | p.Ser121Phe | p.S121F | Q96NM4 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TOX2 | SNV | Missense_Mutation | c.774N>T | p.Arg258Ser | p.R258S | Q96NM4 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
TOX2 | SNV | Missense_Mutation | novel | c.449N>T | p.Asp150Val | p.D150V | Q96NM4 | protein_coding | deleterious(0.04) | probably_damaging(0.925) | TCGA-MY-A5BE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |